First Chewable ADHD Treatment Authorized by Health Canada
Health Canada has authorized the first chewable treatment for patients with attention deficit hyperactivity disorder (ADHD) aged six and older: a chewable table of Vyvanse® (lisdexamfetamine dimesylate).
“With chewable tablets, children with ADHD now have a new option that makes taking a medication like Vyvanse® easier in the morning. The goal of this new delivery administration is to improve medication adherence,” according to incoming CADDRA Chair, Dr. Martin Gignac, M.D., F.R.C.P.(C), Child and Adolescent Psychiatrist, at the Montreal Children’s Hospital, and Clinical Associate Professor, at McGill University. “Ultimately, pharmacotherapy with a medication like Vyvanse® improves ADHD symptom control right from the start in the morning and throughout the day, allowing the child to function optimally at home, at school and with friends.”
Vyvanse® chewable tablets are administered once daily in the morning and are available in six doses: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg. Vyvanse® chewable tablets are expected to be available in fall 2019. The tablets are also indicated for the treatment of moderate to severe binge eating disorder in adults aged 18 and older.
Health Canada’s authorization is based on a study of healthy adult subjects (N=18), which showed that the chewable lisdexamfetamine dimesylate tablet had comparable bioavailability when compared to the capsule formulation after a single-dose oral administration of 60 mg under fasting condition.